CIPROFLOXACIN HYDROCHLORIDE - Generic Drug Details

What are the generic sources for ciprofloxacin hydrochloride and what is the scope of patent protection?

Ciprofloxacin hydrochloride is the generic ingredient in eight branded drugs marketed by Sandoz, Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Pharmobedient, Rising, Rubicon Research, The J Molner, Watson Labs Inc, Lab Salvat, New Heightsrx, Depomed Inc, Bayer Hlthcare, Aiping Pharm Inc, Amneal, Aurobindo Pharma, Barr, Carlsbad, Chartwell, Dr Reddys Labs Ltd, Hikma, Ivax Sub Teva Pharms, Natco, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique, Watson Labs, Yiling, and Cosette Pharms Nc, and is included in thirty-six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty-three drug master file entries for ciprofloxacin hydrochloride. Fifty-three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for CIPROFLOXACIN HYDROCHLORIDE

US Patents:	1
Tradenames:	8
Applicants:	32
NDAs:	36
Drug Master File Entries:	23
Finished Product Suppliers / Packagers:	53
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	327
Patent Applications:	6,125
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIPROFLOXACIN HYDROCHLORIDE
What excipients (inactive ingredients) are in CIPROFLOXACIN HYDROCHLORIDE?	CIPROFLOXACIN HYDROCHLORIDE excipients list
DailyMed Link:	CIPROFLOXACIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Faiz ur rahman	NA
Stanford University	EARLY_PHASE1
Uppsala University	PHASE4

See all CIPROFLOXACIN HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for CIPROFLOXACIN HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 750MG BASE	TABLET;ORAL
		EQ 500MG BASE	TABLET;ORAL
		EQ 250MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for CIPROFLOXACIN HYDROCHLORIDE

Drug Class	Fluoroquinolone Antibacterial Quinolone Antimicrobial
Mechanism of Action	Cytochrome P450 1A2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for CIPROFLOXACIN HYDROCHLORIDE

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for CIPROFLOXACIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Natco	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	075685-002	Jun 9, 2004		DISCN	No	No
Unique	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076639-001	Sep 10, 2004	AB	RX	No	No
New Heightsrx	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	SOLUTION/DROPS;OTIC	217887-001	Nov 5, 2024	AB	RX	No	No
Amneal	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	075939-004	Jun 9, 2004		DISCN	No	No
Aurobindo Pharma	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	077859-001	Apr 26, 2007	AB	RX	No	No
Unique	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076639-002	Sep 10, 2004	AB	RX	No	No

Expired US Patents for CIPROFLOXACIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005	6,488,962
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005	5,972,389
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005	6,635,280
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005	6,340,475

Ciprofloxacin Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

How does ciprofloxacin hydrochloride move through the market?

Ciprofloxacin hydrochloride is a widely used fluoroquinolone antibiotic whose market dynamics are shaped by (1) generic-driven pricing, (2) regulatory and stewardship constraints, (3) hospital versus outpatient demand splits, and (4) ongoing portfolio churn from competitors with differentiated formulations and geographies.

Demand drivers

• Infection mix: Ciprofloxacin is used across respiratory, urinary tract, gastrointestinal, and resistant pathogen settings, with utilization highest where fluoroquinolones remain guideline-concordant and where prescriber behavior supports oral and IV use.
• Route and setting: Sales typically skew toward oral products for chronic and outpatient episodes, with IV/inpatient dosing contributing during acute care outbreaks and resistant infections.
• Geographic variability: Utilization varies by country-level stewardship policies, reimbursement intensity, and local guideline preferences, creating uneven sales trajectories across regions.

Supply and competition

• Generic penetration: The molecule is mature and heavily genericized, making volume growth difficult to translate into meaningful pricing power.
• Therapeutic class competition: Competitive pressure comes from other fluoroquinolones and from non-fluoroquinolone antibiotic classes that gain share when guidelines narrow fluoroquinolone indications.
• Formulation competition: Revenue tilts toward branded or semi-branded formulations where available (dose convenience, local regulatory exclusivity, or supply stability), but generics dominate pricing outcomes.

Pricing structure and profitability pressure

• Price compression is structural: In mature antibiotic markets, incremental unit sales often coexist with lower ASPs due to tendering, national procurement, and multi-source manufacturing.
• Margin dispersion: Profitability depends on whether a company sells branded supply (limited) or competes on generic tenders (high volume, low margin).

What are the financial fundamentals behind the product’s trajectory?

Ciprofloxacin’s financial trajectory is characterized by a long-run pattern: strong early adoption, sustained volume due to broad indication coverage, and then persistent margin decline from generic entry and stewardship-driven indication narrowing.

Typical lifecycle pattern (generic endpoint)

• Peak era: Brand or early exclusivity periods create higher revenue per unit.
• Post-patent period: After widespread generic launch, revenues remain largely volume-led, while pricing and gross margins fall.
• Maturity phase: Revenue stabilizes and grows slowly; profitability tracks manufacturing scale, procurement relationships, and market access.

What investors usually see in financials

• Top-line resilience: Antibiotics with long-established dosing regimens keep demand steady even under lower pricing.
• Earnings volatility at the micro level: Switching procurement policies, API supply dynamics, and quality events can swing margins more than volumes.
• Limited upside from “newness”: For mature small-molecule antibiotics, financial upside usually comes from formulation expansion, regional exclusivity windows, or supply differentiation rather than breakthrough clinical value.

Business drivers that move results in mature markets

• Tender cycles and reimbursement: Revenue growth often tracks procurement calendars more than epidemiology.
• Inventory and supply contracts: API lead times, capacity allocation, and contract renewals can determine quarterly net sales.
• Regulatory actions: Safety label updates or restriction language can reduce fluoroquinolone use in specific cohorts, affecting volume.

How have regulations and stewardship constraints shaped performance?

Ciprofloxacin markets face repeated stewardship pressure tied to fluoroquinolone class risk-benefit scrutiny. These constraints affect both prescriber behavior and formulary positioning.

Stewardship effects on utilization

• Formulary restrictions: When payers or hospitals limit use to specific indications, total addressable volume declines even if the drug stays clinically relevant.
• Alternative prescribing: Wider use of other antibiotic classes can reduce fluoroquinolone share.
• Monitoring and post-market requirements: Compliance costs can rise, increasing total system cost even where the drug remains a standard option.

Safety-related label evolution as a demand variable

Regulatory updates to fluoroquinolone risk communication have been associated with more conservative prescribing patterns. (For class context, see FDA communications on fluoroquinolone safety labeling, including warnings about disabling and potentially irreversible side effects. [1])

Where are the revenue “pressure points” and “pockets of resilience”?

Even in a mature antibiotic, there are identifiable pockets where ciprofloxacin can hold revenue better than peers, typically where guideline adherence and procurement inertia remain stronger.

Pressure points

• Global generic price benchmarks: Multi-source competition forces ASP reduction.
• Indication tightening: Any restriction that narrows fluoroquinolone use reduces annual demand.
• Intense procurement switching: Hospitals can quickly move to the lowest-cost equivalent during tender cycles.

Resilience pockets

• Clinically entrenched use-cases: Where ciprofloxacin is established in treatment pathways, volume can remain durable.
• Hospital IV demand: Acute care use can be less price-sensitive than outpatient usage in certain tender structures.
• Regional manufacturing strength: Supply reliability can protect share if competitors face shortages or quality interruptions.

What does the competitive landscape imply for financial trajectory?

Ciprofloxacin’s competitive reality is multi-dimensional: molecule-level saturation, class-level stewardship limits, and formulation-level differentiation.

Competitive intensity is high

• Many manufacturers: Generic availability is extensive, and competition is active on price and supply chain reliability.
• Class competition is dynamic: Antibiotic cycling guided by local resistance patterns can shift share to substitutes.
• Differentiation is mostly structural: Release form, packaging, and distribution execution matter more than innovation.

Financial outcome in this environment

• Revenue growth is constrained: Unit expansion meets hard ceilings from generic saturation and stewardship restrictions.
• Margins are structurally pressured: Gross margin depends on API sourcing costs, manufacturing yield, and negotiated procurement pricing.
• Share gains come from execution: Companies that secure stable supply and favorable tender position can outperform peers even without higher drug efficacy.

How should business leaders read near-to-mid term market signals?

Market signals for ciprofloxacin generally compress into four leading indicators: tender pricing, formulary access, procurement volume stability, and safety label-driven prescribing changes.

Near-to-mid term watch list

1. Tender pricing trend: ASP decreases typically lead any margin compression.
2. Formulary status: Any tightening by national formularies or hospital committees affects patient volumes.
3. Supply and manufacturing outages: Short supply can lift realized prices temporarily even in generics.
4. Antibiotic stewardship protocols: Policy updates drive utilization shifts across outpatient versus inpatient.

How does ciprofloxacin hydrochloride typically perform across product formats?

Revenue mix is influenced by route and dosage convenience, which can moderate unit economics in generics.

Common commercial splits (typical pattern)

• Oral tablets/suspensions: Usually the largest volume component; pricing is most tender-driven.
• IV formulations: Smaller volume, but can be more insulated when tied to hospital protocols, acute care procurement, or outbreak dosing needs.
• Concentration and pack sizes: Contract-specific packaging can improve realized pricing versus unstructured sales.

What is the overall financial trajectory profile for the drug?

Taken together, ciprofloxacin’s financial trajectory is a mature-product curve: stable or slowly growing revenues supported by volume, with persistent margin erosion driven by generic pricing and constrained by stewardship and labeling.

Trajectory summary

• Top-line: Stable to modestly growing, dominated by volume and procurement access.
• Pricing: Downward pressure from generic competition and tendering.
• Profitability: Margin compression is ongoing; companies win by scale, cost leadership, and supply reliability rather than by price increases.
• Risk: Higher policy and label sensitivity than non-restricted antibiotic classes.

Business implications: what actions tend to matter most?

In ciprofloxacin’s market structure, actions that improve realized pricing or stabilize volume usually drive financial outcomes more than marketing spend.

Execution levers with the highest impact

• API and intermediate cost control to protect gross margins in tender environments.
• Quality and supply continuity to defend hospital contracting and pharmacy group listings.
• Regional commercial concentration discipline to avoid low-return markets when procurement pricing turns unfavorable.
• Portfolio packaging strategy (pack size, dose form readiness) aligned to tender specifications.

---

Key Takeaways

• Mature, generic-driven market: Ciprofloxacin’s revenue behavior is primarily volume-led with sustained ASP and margin pressure.
• Stewardship and safety labeling are demand variables: They influence formulary access and prescribing patterns, particularly in outpatient settings.
• Financial outcomes hinge on execution: Tender pricing, supply reliability, and manufacturing cost position determine who outperforms.
• Near-to-mid term signals are measurable: Watch tender ASP, formulary restrictions, procurement stability, and manufacturing disruptions for directionally reliable indications.

---

FAQs

1. Is ciprofloxacin hydrochloride primarily a volume or pricing story?
   It is primarily a volume story in stabilized access settings, with pricing typically moving down over time due to generic competition and tender dynamics.

2. What factor most affects margins for a mature ciprofloxacin product?
   API and manufacturing cost position, combined with tender pricing and procurement terms, determines gross margin more than product differentiation.

3. How do safety and stewardship policies impact the financial outlook?
   They can tighten prescribing and formulary access, reducing the addressable patient population even when generic supply remains abundant.

4. Where can manufacturers find relative resilience?
   Contracted hospital use, stable formulary placement, and supply continuity tend to protect volumes better than opportunistic, low-contract-price channels.

5. What are the fastest-moving indicators of near-term results?
   Tender cycles (realized pricing), formulary status changes, and supply constraints or manufacturing outages.

---

References

[1] U.S. Food and Drug Administration. (n.d.). FDA updates on fluoroquinolone antibiotics and safety communications. https://www.fda.gov/drugs/drug-safety-and-availability